DE102018120298A1 - A medicine used to treat gout and process for its manufacture - Google Patents

Abstract

The present invention discloses a medicament for treating gout and a method for producing the same. The medicinal product for the treatment of gout includes Herba plantaginis 5-15, Arillus Longan 10-15, Cortex lycii radicis 13-20, Cordyceps 12-28 and Retinervus Luffae Fructus 5-12 by weight. The gout treatment medicine according to the present invention has different ingredients compared to the prior art drugs and can overcome the shortcomings of the prior art drugs.

Description

TECHNICAL AREA

The present invention relates to the field of pharmaceuticals, in particular a pharmaceutical for the treatment of gout and a method for its production.

BACKGROUND

Gout is a disease based on a chronic metabolic disorder. It is a disease characterized by the formation of excessive uric acid in the human body or a decrease in the renal excretion of uric acid, which causes an increased concentration of uric acid in the blood, and is clinically known as hyperuricemia. Uric acid is an end product of purine metabolism and purine is created by the catabolism of human cells. When the uric acid in the blood increases to a certain extent, it is deposited in the body, especially in the joints and kidneys, which leads to repeated attacks of arthritis and even causes joint movement disorders or malformations, which is known clinically as gouty arthritis. The deposition of uric acid in the kidney leads to uric acid kidney damage and damage to the kidney parenchyma, which is known clinically as uric acid nephropathy and also known as gout nephropathy. It can lead to seizures of renal colic, hematuria, hydronephrosis and kidney dysfunction, even cause kidney failure and urine poisoning, making it one of the main causes of gout patient death. Because gout is a chronic, lifelong disease that can last for decades and typically occurs in intermittent seizures, a patient suffering from gout tends to pay less attention to it and will not be sufficiently aware of its malignancy.

Currently, gout is mainly treated by drug administration according to clinical symptoms, during a gout attack, the patient is mainly given colchicine and pain reliever to quickly reduce inflammation and relieve pain, while the patient is intermittently given purine, etc. to reduce uric acid to ward off another attack. In general, all Western medicines currently used to treat gout have serious side effects and are palliative. Also, with regard to intermittent western drug administration, gout will return quickly after drug administration is discontinued, causing a transitional gout attack due to excessive uric acid dissolution.

However, the treatment effects of the above treatment methods are not good. In addition, the current drugs have different toxic effects. There is therefore an urgent need for a new medication to treat gout in order to overcome the disadvantages mentioned above.

SUMMARY OF THE INVENTION

In view of the above problem, the present invention provides a gout treatment drug capable of solving the above problems, or at least a part of the above problems, for overcoming the deficiencies of a poor treatment effect of the drugs from the State of the art is used.

According to a first aspect, the present invention provides a medicament for the treatment of gout, which is based on parts by weight of Herba plantaginis (Chinese gold thread) 5-15, Arillus Longan (cork tree bark) 10-15, Cortex lycii radicis (tragacanth root) 13-20, Cordyceps (Chinese angelica) 12-28 and Retinervus Luffae Fructus (Chinese winter herb) 5-12.

The drug for treating gout according to the present invention has different ingredients compared to the drugs from the prior art and can overcome the shortcomings of the drugs from the prior art.

DETAILED DESCRIPTION OF THE EMBODIMENTS

In one embodiment of the present invention, there is provided a medicament for the treatment of gout, which is based on parts by weight of Herba plantaginis 5-15, Arillus Longan 10-15, Cortex lycii radicis 13-20, Cordyceps 12-28 and Retinervus Luffae Fructus 5-12 includes.

The medicinal product also contains Carapax Eretmochelyos (Hawksbill Turtle Shell) 20-30 by weight.

The drug also contains Rhizoma Smilacis Glabrae (stinging rhizome) 12-18 by weight.

The above Carapax Eretmochelyos and Rhizoma Smilacis Glabrae are just a few specific examples, but are not meant to be limiting. Other materials such as wolfberry fruit, Gynostemma pentaphyllum ( Immortality herb), 12 semen Astragali Complanati (flat-stemmed tragacanth), Radix Dipsaci (Chinese card root), Herba Eclipta (ecliptic herb), Fructus Ligustri Lucidi (glossy privet), etc. are also possible. Other materials in question are not described in detail.

Optionally, in one embodiment of the present invention, materials for stimulating blood circulation, such as Curcuma longa (turmeric), Ligusticum chuanxiong Hort (Szechuan lovage), Radix Salviae Miltiorrhizae (red sage) and rapontica root can be added.

In addition, in one embodiment of the present invention, in order to improve the pharmacological effect, the medicament can also include heat-removing materials, such as, for example, Fructus Gardeniae (Jasmine Gloss Fruit), Flos Chrysanthemi (Chrysanthemum Flower), Semen Cassiae (Cassia Seeds), Cortex Fraxini (Ash Bark), Radix Sophorae Flavescentis (Cord Tree Root), Flos Chrysanthemi Indici (Wild Chrysanthemum Flowers), Andrographis paniculata (Kalmegh) etc.

In addition, the drug may further include materials that wick moisture and promote diuresis, such as Herba Sedi (fatty hens), Abrus herb, etc.

In addition, the drug may further comprise materials that warm from the inside, such as pepper.

In one embodiment of the present invention, the dosage form of the drug is at least one of the following: a film-coated tablet, a sugar-coated tablet, an enteric-coated tablet, a dispersible tablet, a capsule, a granulate, a decoction, a mixture, a syrup, a medicinal wine , an injection, an oral solution or a viscous liquid.

In one embodiment of the present invention, the medicament may have a dosage form for oral administration.

In one embodiment of the present invention, the dosage form for oral administration optionally comprises tablets, capsules, pills, injections, sustained release preparations and controlled release preparations.

The pharmaceutical composition of the embodiment provided in the present invention or the pharmaceutical composition comprising it can be administered in a single dosage form via the intestinal tract, the nasal cavity, the oral mucosa, the eye, the lungs, the respiratory tract, the skin, the rectum, etc. are administered and can be used in the form of oral administration, intravenous injection, intramuscular injection and subcutaneous injection.

The dosage form for administration can be a liquid dosage form, a solid dosage form or a semi-solid dosage form. The liquid dosage form can be a solution, emulsion, suspension, injection (including water injection, powder injection and transfusion), eye drops, nose drops, lotion and liniment. The solid dosage form can be a tablet (including an uncoated tablet, enteric-coated tablet, buccal tablet, dispersible tablet, chewable tablet, effervescent tablet, an oral tablet), a capsule (including a hard capsule, soft capsule, enteric-coated capsule), granules, powder, Pellet, drip pill, suppository, film, paster, aerosol, spray, etc. The semi-solid dosage form can be an ointment, a gel, a paste, etc. The dosage form of the drug is preferably a tablet, a capsule, a pill and an injection.

The medicament according to one embodiment of the present invention can be processed into a conventional preparation, a sustained release preparation, a controlled release preparation, a targeting preparation and various granule administration preparations.

In one embodiment of the present invention, various adjuvants such as diluents, binders, humectants, disintegrants, lubricants, and flow regulators can be used to make the pharmaceutical of the present invention into tablets. The diluent can be starch, dextrin, sucrose, glucose, lactose, mannitol, sorbitol, xylitol, microcrystalline cellulose, calcium sulfate, calcium hydrogen phosphate, calcium carbonate and the like; the humectant can be water, ethanol, isopropanol and the like; the binder can be starch slurry, dextrin, syrup, honey, glucose solution, microcrystalline cellulose, gum arabic slurry, gelatin slurry, sodium carboxymethyl cellulose and methyl cellulose; the disintegrant can be dry starch, microcrystalline cellulose, low substituted hydroxypropyl cellulose; and the lubricant and flow control agent can be talc, silica, stearate, liquid paraffin and the like.

Furthermore, the drug can also be a coated tablet, for example one with sugar coated tablet, film-coated tablet, enteric-coated tablet and the like.

When the drug is made into a capsule, the active ingredient can be made into granules or pellets with the addition of diluents, binders and disintegrants, which are then placed in a hard or soft capsule.

When the medicine is processed into an injection, the solvent can be water, ethanol, isopropanol, propylene glycol or a mixture of these. Furthermore, an appropriate amount of solubilizing agent, cosolvent, pH regulator, osmotic pressure adjusting agent may be added.

In addition, the drug can be mixed with colorants, preservatives, perfumes, correctives or other auxiliary substances.

• Ein erster Schritt: Abwiegen nach Gewichtsanteilen: Herba plantaginis 5-15, Arillus Longan 10-15, Cortex lycii radicis 13-20, Cordyceps 12-28 und Retinervus Luffae Fructus 5-12, Mischen, um eine Mischung zu erhalten und Pulverisieren der Mischung;
• Ein zweiter Schritt: Zugeben von 70% Ethanol zu der pulverisierten Mischung in einem Gewichtsverhältnis von (2-3): 1;
• Ein dritter Schritt: Zweimaliges Durchführen einer Rückfluss-Extraktion des Resultats, jeweils für 2-3 h und Filtern, um zwei Filtrate zu erhalten;
• Ein vierter Schritt: Mischen der zwei Filtrate und Konzentrieren, um das Ethanol zu entfernen, um eine Extraktionslösung als Zielarzneimittelzubereitung zu erhalten.

In one embodiment of the present invention there is provided a process for the manufacture of the above medicament which comprises the following steps:

• A first step: weighing by weight: Herba plantaginis 5-15, Arillus Longan 10-15, Cortex lycii radicis 13-20, Cordyceps 12-28 and Retinervus Luffae Fructus 5-12, mixing to obtain a mixture and pulverizing the mixture ;
• A second step: add 70% ethanol to the powdered mixture in a weight ratio of (2-3): 1;
• A third step: performing a reflux extraction of the result twice, each for 2-3 h and filtering to obtain two filtrates;
• A fourth step: mix the two filtrates and concentrate to remove the ethanol to obtain an extraction solution as the target drug preparation.

Below are some specific examples of the method of manufacturing the medicament for treating gout.

example 1

• A first step: weighing by weight: Herba plantaginis 5-15, Arillus Longan 10-15, Cortex lycii radicis 13-20, Cordyceps 12-28 and Retinervus Luffae Fructus 5-12, mixing to obtain a mixture and pulverizing the mixture ;
• A second step: boil the mixture twice with water, each for 4 h at 30 ° C. with the addition of 10 ml of water at intervals of 30 minutes and filtering in order to obtain two filtrates;
• A third step: mixing the two filtrates and adding 70% ethanol, the weight of the ethanol being twice the total weight of the raw materials;
• A fourth step: performing a reflux extraction of the result twice at room temperature, each for 2 h and filtering to obtain two filtrates;
• A fifth step: mixing the two filtrates and concentrating to remove the ethanol to obtain an extraction solution as the target drug preparation.

Example 2

• A first step: weighing by weight: Herba plantaginis 5, Arillus Longan 10, Cortex lycii radicis 13, Cordyceps 28 and Retinervus Luffae Fructus 12;
• A second step: pulverize the above materials into fine powder, filter with a 200 mesh sieve and mix evenly to obtain a pulverized mixture;
• A third step: add 70% ethanol to the powdered mixture in a weight ratio of 3: 1;
• A fourth step: performing a reflux extraction of the result twice, each for 3 h and filtering to obtain two filtrates; and
• a fifth step: mixing the two filtrates and concentrating to remove the ethanol to obtain an extraction solution as the target drug preparation.

Example 3

• A first step: weighing by weight Herba plantaginis 5, Arillus Longan 10, Cortex lycii radicis 13, Cordyceps 28 and Retinervus Luffae Fructus 12;
• A second step: pulverize the above materials into fine powder, filter with a 200 mesh sieve and mix evenly to obtain a pulverized mixture;
• A third step: add water to the powdered mixture above and soak for at least 8 hours until the mixture is fully soaked;
• A fourth step: boil the mixture twice with water, each for 4 h at 30 ° C. with the addition of 10 ml of water at intervals of 30 minutes and filtering in order to obtain two filtrates;
• A fifth step: mixing the two filtrates and adding 70% ethanol, the weight of the ethanol being three times the total weight of the raw materials;
• A sixth step: performing a reflux extraction of the result twice at room temperature, each for 3 h and filtering to obtain two filtrates; and
• a seventh step: mixing the two filtrates and concentrating to remove the ethanol to obtain an extraction solution as the target drug preparation.

The drug for treating gout according to the present invention has different ingredients compared to the drugs from the prior art and can overcome the shortcomings of the drugs from the prior art.

Claims (5)

A drug for the treatment of gout, which comprises, by weight, Herba plantaginis 5-15, Arillus Longan 10-15, Cortex lycii radicis 13-20, Cordyceps 12-28 and Retinervus Luffae Fructus 5-12. The medicine used to treat gout after Claim 1 also includes Carapax Eretmochelyos 20-30 by weight. The medicine used to treat gout after Claim 1 also includes Rhizoma Smilacis Glabrae 12-18 by weight. The medicine used to treat gout after Claim 1 , wherein the dosage form of the drug is at least one of the following: a film-coated tablet, a sugar-coated tablet, an enteric-coated tablet, a dispersible tablet, a capsule, a granulate, a decoction, a mixture, a syrup, a medicinal wine, an injection, an oral solution and a viscous oral fluid. A method of manufacturing the medicament according to one of the Claims 1 - 4 , which includes the following steps: A first step: weighing by weight: Herba plantaginis 5-15, Arillus Longan 10-15, Cortex lycii radicis 13-20, Cordyceps 12-28 and Retinervus Luffae Fructus 5-12, mix to make one Obtain mixture and pulverize the mixture; A second step: add 70% ethanol to the powdered mixture in a weight ratio of (2-3): 1; A third step: performing a reflux extraction of the result twice, each for 2-3 h and filtering to obtain two filtrates; and a fourth step: mixing the two filtrates and concentrating to remove the ethanol to obtain an extraction solution as a target drug preparation.